Who are clopidogrel/abciximab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clopidogrel-abciximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

clopidogrel/abciximab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

clopidogrel/abciximab (clopidogrel/abciximab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual antiplatelet agent (P2Y12 inhibitor + glycoprotein IIb/IIIa inhibitor). Area: Cardiovascular.

marketed Dual antiplatelet agent (P2Y12 inhibitor + glycoprotein IIb/IIIa inhibitor) P2Y12 receptor (clopidogrel); glycoprotein IIb/IIIa integrin (abciximab) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

clopidogrel/abciximab (clopidogrel/abciximab) — I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio. This combination uses clopidogrel to inhibit platelet aggregation via P2Y12 receptor blockade and abciximab to block the glycoprotein IIb/IIIa receptor, providing dual antiplatelet effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
clopidogrel/abciximab TARGET	clopidogrel/abciximab	I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio	marketed	Dual antiplatelet agent (P2Y12 inhibitor + glycoprotein IIb/IIIa inhibitor)	P2Y12 receptor (clopidogrel); glycoprotein IIb/IIIa integrin (abciximab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual antiplatelet agent (P2Y12 inhibitor + glycoprotein IIb/IIIa inhibitor) class)

I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). clopidogrel/abciximab — Competitive Intelligence Brief. https://druglandscape.com/ci/clopidogrel-abciximab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab